ICL vs STAA: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
ICL is the larger of the two ($5.31B market cap): the incumbent the market prices for continued execution (9.05x forward earnings, beta 1.00). STAA is the smaller challenger ($1.21B), actually pricier on forward earnings (21.26x): more room to run, but more to prove. If you believe STAA earns its premium (21.26x forward earnings, so the market expects more from it), STAA fits. If you believe in paying less for profit, ICL fits at 9.05x.
ICL vs STAA: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ICL | STAA | What it tells you |
|---|---|---|---|
| Market cap | $5.31B | $1.21B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 9.05 | 21.26 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 16.46 | 2,408.00 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.00 | 1.20 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 1% of range | 42% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.85 | 3.21 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ICL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ICL and STAA affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ICL and STAA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ICL and STAA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does ICL Group Ltd (ICL) do?
ICL Group Ltd. runs four businesses out of a mineral base most competitors cannot replicate. Industrial Products extracts bromine from the highly concentrated Dead Sea brine and turns it into flame retardants, clear brine fluids and specialty minerals, making ICL the largest elemental bromine producer in the world alongside Albemarle and Lanxess. Potash comes from solar evaporation ponds at Sodom in Israel and from underground mines in Catalonia, Spain. Phosphate Solutions works phosphate rock from the Negev and China into fertilisers and higher value food and industrial specialties, and Growing Solutions sells controlled release and water soluble fertilisers, biostimulants and micronutrients into agriculture, turf and ornamental markets. The company employs about ~12,000 people, reports in US dollars under IFRS as a foreign private issuer, and had ~1.29 billion ordinary shares outstanding at the end of 2025.
What does STAAR Surgical (STAA) do?
STAAR Surgical, based in Lake Forest, California, makes implantable lenses for vision correction. Its main product is the EVO Implantable Collamer Lens (ICL), a soft lens that a surgeon slips behind the iris and in front of the eye's natural lens, correcting myopia, with or without astigmatism, without removing corneal tissue the way LASIK or SMILE do. The lens can be taken out later. It is sold in more than 75 countries, gained U.S. FDA approval in its EVO form in 2022, and is manufactured in Monrovia, California and in Switzerland. Nearly all revenue comes from the ICL family, including the newer EVO+ with a larger optic and toric versions for astigmatism.
ICL vs STAA: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ICL drivers: Potash pricing against a low cost Dead Sea position; Bromine and an improving specialty mix.
- STAA drivers: China demand and pricing; Growth outside China.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The Dead Sea Works concession covering ~652 square kilometres runs only to March 31, 2030, and ICL must win the successor concession from the Israeli state on terms the state sets, which is the largest open question in the equity. For STAA, close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return.
ICL or STAA: which should you pick?
If the story you believe is ICL's (Potash pricing against a low cost Dead Sea position), ICL is the more direct way to own it; if it is STAA's (China demand and pricing), STAA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ICL and STAA guides.
ICL vs STAA: the full fundamentals
ICL. ICL reports in US dollars under IFRS even though it is an Israeli issuer filing a Form 20-F, so no currency translation is needed to read these numbers. The reported trailing P/E of about 16.5x still carries part of 2025's roughly ~$293 million of impairments, closure charges and a Dead Sea water fee provision; on 2027 consensus EPS of about $0.45 the multiple at the November 20, 2026 price is near 9x. Dividend policy is a payout of up to ~50% of adjusted annual net income, and the share-price decline has lifted the trailing yield to about 4.7%.
STAA. Trailing revenue of about $328 million combines the weak fourth quarter of 2025 (~$57.8 million and an ~$18.3 million loss) with three strong 2026 quarters, so the trailing GAAP profit of roughly zero understates the current run rate. Taking off the cash, enterprise value is about $1.0 billion, around 3.1 times trailing sales and about 13 times nine-month adjusted EBITDA annualized; the forward P/E is about 21 on 2027 EPS estimates near $1.13. The shares sit about 22% below Alcon's rejected $30.75 offer and under the ~$28.56 mean analyst target, with a Buy average from nine analysts.
Headline figures (approximate, November 2026): ICL shows revenue (ttm) ~$7.8B, with Q3 2026 sales of ~$1.91B up ~3% year over year, adjusted ebitda Q3 2026 ~$402M (+~1%); FY2026 guidance reiterated at ~$1.5B to ~$1.7B, net income and eps (ttm) ~$310M; ~$0.25 reported; Q3 adjusted EPS $0.10, in line, p/e ~16.5x trailing reported, ~9x forward; STAA shows revenue (ttm through q3 2026) ~$328M, net income (ttm through q3 2026) ~breakeven (~$18.8M for 9M 2026), adjusted ebitda (9m 2026) ~$58.8M, gross margin (q3 2026) ~70.9% (82.2% a year earlier).
The bottom line: ICL vs STAA
ICL and STAA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ICL and STAA exposure against your real portfolio. It is not an investment adviser.
Wondering how ICL or STAA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about ICL Group Ltd
Ask Walnut's AI anything about ICL and see how it fits what you own.
FAQ
What is the difference between ICL and STAA?
+
ICL Group Ltd. STAAR Surgical, based in Lake Forest, California, makes implantable lenses for vision correction. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ICL or STAA the better stock?
+
Neither is universally better. ICL is the larger incumbent; STAA is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ICL or STAA?
+
On forward P/E (as of November 2026), ICL trades at 9.05x and STAA at 21.26x, so ICL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ICL and STAA?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ICL vs STAA?
+
ICL: The Dead Sea Works concession covering ~652 square kilometres runs only to March 31, 2030, and ICL must win the successor concession from the Israeli state on terms the state sets, which is the largest open question in the equity. Israeli country risk is concrete rather than theoretical here: the security situation has produced recurring charges (~$8 million in the third quarter, mostly higher shipping costs), shekel appreciation lifts a cost base that sells in dollars, and regional shipping disruption affects both input costs and exports. Earnings remain levered to potash and phosphate pricing, so a soft grain year would give back a good part of the 2026 recovery; third quarter adjusted EPS was flat at $0.10, raw material costs are pressuring phosphate and plant nutrition margins, and the share price has fallen about 14% in the past month alone. Net financial liabilities stood at ~$2,626 million at September 30, 2026, up ~$366 million since the end of 2025 after an ~$800 million ten year note issue at ~6.036%, comfortable at roughly ~1.6 times adjusted EBITDA but less forgiving if prices turn. Several Israeli environmental and planning matters remain open, including petitions over the Pond 4 reuse plan and an appeal against the dismissal of a Haifa Bay air pollution class action, and none of these are securities fraud claims. STAA: Close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. Chinese competition is now real. Eyebright Medical's Loong Crystal PR phakic lens was approved by China's NMPA in January 2025, and a small Fudan University study found similar efficacy and safety against the EVO ICL in paired eyes. Hospital procurement policy in China, including volume-based purchasing that has squeezed prices for cataract lenses, could reach phakic lenses. Tariffs already cut third-quarter gross margin by several points, and U.S.-origin product sold into China is still subject to them. Japan and South Korea are declining. The ICL is effectively the whole company, so a safety signal, a recall or a manufacturing problem at either plant would hit every line of the income statement. Finally, the share price no longer has a takeover floor. Holders who rejected $30.75 are relying on the standalone plan, and the stock has traded between ~$15.59 and ~$35.87 over the past 52 weeks.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ICL or STAA; figures are approximate and dated (as of November 2026). Verify current data before investing.